AI Engines For more Details: Perplexity Kagi Labs You
Mechanism of Action: Guanethidine sulfate belongs to a class of medications known as sympatholytics or adrenergic neuron blockers. It works by inhibiting the release of norepinephrine from nerve endings, which reduces sympathetic nervous system activity. This leads to vasodilation (widening of blood vessels) and a subsequent decrease in blood pressure.
Treatment of Hypertension: Guanethidine sulfate was historically used as an antihypertensive medication to lower blood pressure in patients with essential hypertension (high blood pressure without an identifiable cause). It was particularly useful in patients who did not respond adequately to other antihypertensive agents.
Limited Use: Despite its efficacy in lowering blood pressure, guanethidine sulfate is rarely used today due to several limitations and side effects associated with its use. These include the need for frequent dosing, slow onset of action, and a high incidence of adverse effects.
Adverse Effects: Guanethidine sulfate can cause a range of side effects, some of which can be severe. Common side effects include orthostatic hypotension (a sudden drop in blood pressure upon standing), dizziness, lightheadedness, weakness, fatigue, gastrointestinal disturbances (such as nausea and diarrhea), and sexual dysfunction.
Orthostatic Hypotension: Orthostatic hypotension is one of the most significant side effects of guanethidine sulfate. It occurs due to the medication's ability to reduce sympathetic tone, leading to inadequate compensation for changes in body position. Patients may experience symptoms such as dizziness, lightheadedness, or fainting when transitioning from lying down to standing up.
Central Nervous System Effects: Guanethidine sulfate can cross the blood-brain barrier and exert effects on the central nervous system. This may result in side effects such as sedation, confusion, depression, and cognitive impairment.
Cardiovascular Effects: In addition to lowering blood pressure, guanethidine sulfate may also affect heart rate and rhythm. It can cause bradycardia (slow heart rate) and may exacerbate conduction abnormalities in patients with pre-existing cardiac conditions.
Withdrawal Rebound Hypertension: Abrupt discontinuation of guanethidine sulfate can lead to rebound hypertension, characterized by a sudden and significant increase in blood pressure. Therefore, the medication should be tapered off gradually under medical supervision when discontinuing treatment.
Contraindications and Precautions: Guanethidine sulfate is contraindicated in patients with hypersensitivity to the medication, severe bradycardia, heart block, or pheochromocytoma (a rare adrenal gland tumor). It should be used with caution in patients with pre-existing cardiovascular disease, renal impairment, or hepatic impairment.
Interactions with Other Medications: Guanethidine sulfate may interact with other medications that affect blood pressure or sympathetic nervous system activity. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting guanethidine sulfate.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Subdoligranulum variabile | species | Decreases |
0 | 1 | Vescimonas fastidiosa | species | Decreases |
0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
0 | 1 | Simiaoa sunii | species | Decreases |
0 | 1 | Coprococcus eutactus | species | Decreases |
0 | 1 | Clostridium sp. SY8519 | species | Decreases |
0 | 1 | Clostridium sp. M62/1 | species | Decreases |
0 | 1 | Wujia chipingensis | species | Decreases |
0 | 1 | Ruminococcus champanellensis | species | Decreases |
0 | 1 | Faecalibacterium sp. I4-1-79 | species | Decreases |
0 | 1 | Coprococcus sp. ART55/1 | species | Decreases |
0 | 1 | Ligilactobacillus ruminis | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Faecalibacterium duncaniae | species | Decreases |
0 | 1 | Eubacterium ventriosum | species | Decreases |
0 | 1 | Faecalibacterium sp. HTF-F | species | Decreases |
0 | 1 | Wansuia hejianensis | species | Decreases |
0 | 1 | Coprococcus comes | species | Decreases |
0 | 1 | Faecalibacterium sp. IP-1-18 | species | Decreases |
0 | 1 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Vescimonas coprocola | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
0 | 1 | Faecalibacterium sp. I4-3-84 | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Lachnospira eligens | species | Decreases |
0 | 1 | Oscillibacter hominis | species | Decreases |
0 | 1 | Roseburia intestinalis | species | Decreases |
0 | 1 | Faecalibacterium sp. I2-3-92 | species | Decreases |
0 | 1 | Qiania dongpingensis | species | Decreases |
0 | 1 | Intestinimonas butyriciproducens | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
0 | 1 | Pusillibacter faecalis | species | Decreases |
0 | 1 | Blautia obeum | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
0 | 1 | Massilistercora timonensis | species | Decreases |
0 | 1 | [Ruminococcus] lactaris | species | Decreases |
0 | 1 | Faecalibacterium sp. I3-3-89 | species | Decreases |
0 | 1 | Faecalibacterium sp. IP-3-29 | species | Decreases |
0 | 1 | [Clostridium] hylemonae | species | Decreases |
0 | 1 | Flintibacter sp. KGMB00164 | species | Decreases |
0 | 1 | Catenibacterium mitsuokai | species | Decreases |
0 | 1 | Maliibacterium massiliense | species | Decreases |
0 | 1 | Intestinibaculum porci | species | Decreases |
0 | 1 | Dorea formicigenerans | species | Decreases |
0 | 1 | Treponema peruense | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.4 | 0.1 | 3 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.1 | 2 |
Allergic Rhinitis (Hay Fever) | 0.7 | 0.5 | 0.4 |
Allergies | 1 | 0.5 | 1 |
Allergy to milk products | 0.5 | 0.3 | 0.67 |
Alopecia (Hair Loss) | 0.1 | -0.1 | |
Alzheimer's disease | 0.9 | 1.5 | -0.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.1 | 2 |
Ankylosing spondylitis | 0.3 | 0.1 | 2 |
Anorexia Nervosa | 0.5 | 0.9 | -0.8 |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Asthma | 1.3 | 0.4 | 2.25 |
Atherosclerosis | 0.4 | 0.6 | -0.5 |
Atrial fibrillation | 0.5 | 0.2 | 1.5 |
Autism | 1.6 | 1.3 | 0.23 |
Autoimmune Disease | 0.1 | 0.5 | -4 |
Barrett esophagus cancer | 0 | 0.1 | 0 |
benign prostatic hyperplasia | 0 | 0.1 | 0 |
Biofilm | 0.4 | 0.4 | |
Bipolar Disorder | 0.5 | 0.2 | 1.5 |
Brain Trauma | 0.1 | 0.3 | -2 |
Breast Cancer | 0.1 | 0.1 | |
Cancer (General) | 0 | 1 | 0 |
Carcinoma | 0.4 | 0.2 | 1 |
Celiac Disease | 0.6 | 0.2 | 2 |
Cerebral Palsy | 0.5 | 0.3 | 0.67 |
Chronic Fatigue Syndrome | 0.8 | 0.8 | 0 |
Chronic Kidney Disease | 0.3 | 0.5 | -0.67 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.3 | 1 |
Chronic Urticaria (Hives) | 0.5 | 0.2 | 1.5 |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
Cognitive Function | 0.3 | 0.6 | -1 |
Colorectal Cancer | 1.6 | 0.8 | 1 |
Constipation | 0.1 | 0.2 | -1 |
Coronary artery disease | 0.2 | 0.5 | -1.5 |
COVID-19 | 1 | 1.4 | -0.4 |
Crohn's Disease | 1.2 | 0.7 | 0.71 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.1 | 0.3 | -2 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 0.4 | 0.4 | 0 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 1.8 | 2 | -0.11 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.5 | 0.9 | -0.8 |
Endometriosis | 0.4 | 0.2 | 1 |
Eosinophilic Esophagitis | 0 | 0.1 | 0 |
Epilepsy | 1.2 | 0.3 | 3 |
erectile dysfunction | 0.5 | 0.5 | |
Fibromyalgia | 0.8 | 0.5 | 0.6 |
Functional constipation / chronic idiopathic constipation | 1 | 0.8 | 0.25 |
gallstone disease (gsd) | 0.7 | 0.2 | 2.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.2 | 0.5 |
Generalized anxiety disorder | 0.3 | 0.5 | -0.67 |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.2 | 0.3 | -0.5 |
Graves' disease | 0.2 | 0.4 | -1 |
Gulf War Syndrome | 0.4 | 0.2 | 1 |
Halitosis | 0.3 | 0.1 | 2 |
Hashimoto's thyroiditis | 0.5 | 0.1 | 4 |
Heart Failure | 0.9 | 0.2 | 3.5 |
hemorrhagic stroke | 0.1 | 0.1 | |
Hidradenitis Suppurativa | 0.2 | 0.2 | |
High Histamine/low DAO | 1.2 | 1.2 | |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
hyperglycemia | 0.4 | 0.2 | 1 |
hypertension (High Blood Pressure | 0.4 | 1 | -1.5 |
Hypoxia | 1.1 | 1.1 | |
IgA nephropathy (IgAN) | 0.3 | 0.7 | -1.33 |
Inflammatory Bowel Disease | 2.4 | 1.3 | 0.85 |
Insomnia | 0.5 | 0.4 | 0.25 |
Intelligence | 0.5 | 0.5 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1.1 | 0.7 | 0.57 |
ischemic stroke | 0.3 | 0.3 | 0 |
Liver Cirrhosis | 1.7 | 0.8 | 1.13 |
Long COVID | 0.6 | 0.7 | -0.17 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0 | 0 | |
Lymphoma | 0 | 0 | |
Mast Cell Issues / mastitis | 0.2 | 0.2 | |
ME/CFS with IBS | 0.4 | 0.6 | -0.5 |
ME/CFS without IBS | 0.4 | 0.3 | 0.33 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.2 | 0.2 | 0 |
Metabolic Syndrome | 1.2 | 1.3 | -0.08 |
Mood Disorders | 2.3 | 1.4 | 0.64 |
multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
Multiple Sclerosis | 1.6 | 1.8 | -0.13 |
Multiple system atrophy (MSA) | 0.5 | 0.5 | |
myasthenia gravis | 0.1 | 0.5 | -4 |
neuropathic pain | 0.7 | -0.7 | |
Neuropathy (all types) | 0.1 | 0.3 | -2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.4 | 1.25 |
NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
Obesity | 1.4 | 2 | -0.43 |
obsessive-compulsive disorder | 0.9 | 0.2 | 3.5 |
Osteoarthritis | 0.5 | 0.3 | 0.67 |
Osteoporosis | 0.6 | 0.2 | 2 |
pancreatic cancer | 0.2 | 0.1 | 1 |
Parkinson's Disease | 1.4 | 1.3 | 0.08 |
Polycystic ovary syndrome | 1.2 | 0.7 | 0.71 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.3 | |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
primary biliary cholangitis | 0.1 | 0.5 | -4 |
Primary sclerosing cholangitis | 0.7 | 0.6 | 0.17 |
Psoriasis | 0.8 | 0.3 | 1.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.8 | -0.14 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 1.2 | 0.6 | 1 |
scoliosis | 0.2 | 0.1 | 1 |
Sjögren syndrome | 0.2 | 0.2 | 0 |
Sleep Apnea | 0 | 0.3 | 0 |
Slow gastric motility / Gastroparesis | 0.2 | 0.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
Stress / posttraumatic stress disorder | 0.7 | 0.3 | 1.33 |
Systemic Lupus Erythematosus | 1 | 0.3 | 2.33 |
Tic Disorder | 0.1 | 0.3 | -2 |
Tourette syndrome | 0.1 | 0.1 | 0 |
Type 1 Diabetes | 0.7 | 0.7 | 0 |
Type 2 Diabetes | 1.1 | 1.3 | -0.18 |
Ulcerative colitis | 1.8 | 1.3 | 0.38 |
Unhealthy Ageing | 0.5 | 0.2 | 1.5 |
Vitiligo | 0.5 | 0.5 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]